Syndax Pharmaceuticals Inc
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $72.80M | $-0.55 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | During market hours | $64.90M | $-0.48 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | During market hours | $68.70M | $-0.78 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | During market hours | $45.90M | $-0.70 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | During market hours | $38.00M | $-0.83 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | During market hours | $20.04M | $-0.98 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | Before market open | $7.70M | $-1.10 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | During market hours | $12.50M | $-0.98 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total research and development plus selling, general and administrative expensesnon-GAAP | full year of 2026 | $400.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Syndax Pharmaceuticals filed with the SEC
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2026 Financial Results and Business Update August 4, 2026 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Other events · EX-99.1 to Form 8-K
Syndax 2026 R&D Event July 14, 2026 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
First Quarter 2026 Financial Results and Business Update April 30, 2026 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44 th Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Third Quarter Financial Results Presentation / November 3, 2025
Results of operations · EX-99.2 to Form 8-K
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2025 Financial Results Presentation / August 4, 2025
Results of operations · EX-99.2 to Form 8-K
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and
Results of operations · Other events · EX-99.1 to Form 8-K
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Other events · EX-99.1 to Form 8-K
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Other events · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
Results of operations · Executive or director change · EX-99 to Form 8-K
Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99 to Form 8-K
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K